Salbutamol CF may be available in the countries listed below.
Salbutamol is reported as an ingredient of Salbutamol CF in the following countries:
Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Salbutamol CF in the following countries:
International Drug Name Search
Risperidona Merck may be available in the countries listed below.
Risperidone is reported as an ingredient of Risperidona Merck in the following countries:
International Drug Name Search
Azatioprina Asofarma may be available in the countries listed below.
Azathioprine is reported as an ingredient of Azatioprina Asofarma in the following countries:
International Drug Name Search
Cefotaxim MIP may be available in the countries listed below.
Cefotaxime sodium salt (a derivative of Cefotaxime) is reported as an ingredient of Cefotaxim MIP in the following countries:
International Drug Name Search
Terbasmin Turbuhaler Singad may be available in the countries listed below.
Terbutaline sulfate (a derivative of Terbutaline) is reported as an ingredient of Terbasmin Turbuhaler Singad in the following countries:
International Drug Name Search
Generic Name: dihydroergotamine (injection) (dye HYE droe er GOT a meen)
Brand Names: D.H.E. 45
Dihydroergotamine is in a group of drugs called ergot alkaloids (ER-got AL-ka-loids). It works by narrowing the blood vessels around the brain and affects blood flow patterns that are associated with certain types of headaches.
Dihydroergotamine injection is used to treat a migraine or cluster headache attack. This medication will only treat a headache that has already begun. It will not prevent headaches or reduce the number of attacks.
Dihydroergotamine injection may also be used for purposes not listed in this medication guide.
Also tell your doctor about all of your medical conditions, especially breathing problems, high blood pressure, ischemic bowel disease, liver or kidney disease, or risk factors for heart disease.
a history of heart disease, angina (chest pain), blood circulation problems, or history of a heart attack or stroke;
coronary artery disease or "hardening of the arteries";
uncontrolled high blood pressure;
severe liver or kidney disease;
a serious infection called sepsis; or
if you have recently had heart or blood vessel surgery (such as bypass surgery).
conivaptan (Vaprisol), imatinib (Gleevec), isoniazid (for treating tuberculosis), or nefazodone (an antidepressant);
diclofenac (Arthrotec, Cataflam, Voltaren, Flector Patch, Solareze);
clarithromycin (Biaxin), erythromycin (E.E.S., EryPed, Ery-Tab, Erythrocin), or telithromycin (Ketek);
clotrimazole (Mycelex Troche), itraconazole (Sporanox), ketoconazole (Extina, Ketozole, Nizoral, Xolegal), or voriconazole (Vfend);
heart or blood pressure medication such as diltiazem (Cardizem, Dilacor, Tiazac), nicardipine (Cardene), quinidine (Quin-G), or verapamil (Calan, Covera, Isoptin, Verelan); or
HIV/AIDS medicine such as atazanavir (Reyataz), delavirdine (Rescriptor), fosamprenavir (Lexiva), indinavir (Crixivan), nelfinavir (Viracept), saquinavir (Invirase, Fortovase), or ritonavir (Norvir).
Dihydroergotamine can cause rare but serious side effects on the heart, including heart attack or stroke. To make sure you can safely take dihdroergotamine, tell your doctor if you have any of these other conditions:
breathing problems;
high blood pressure;
ischemic bowel disease;
liver or kidney disease; or
coronary heart disease (or risk factors that include diabetes, menopause, smoking, being overweight, having high blood pressure or high cholesterol, having a family history of coronary artery disease, being older than 40 and a man, or being a woman who has had a hysterectomy).
Use exactly as prescribed by your doctor. Never use more than your prescribed dose of dihydroergotamine. Tell your doctor if the medicine seems to stop working as well in treating your migraine attacks.
Dihydroergotamine is injected into a muscle. You may be shown how to use injections at home. Do not self-inject this medicine if you do not fully understand how to give the injection and properly dispose of used needles and syringes.
Use dihydroergotamine injection as soon as you notice headache symptoms, or after an attack has already begun.
If your headache does not completely go away, you may use a second injection after 1 hour has passed, and a third injection if needed after another hour has passed (a total of 3 injections).
Do not use more than a total of 3 injections of this medication in any 24-hour period. Do not use more than a total of 6 injections over a period of 7 days.
Dihydroergotamine injection should be clear and colorless. Do not use if the liquid has changed colors or has particles in it. Call your doctor for a new prescription.
If you use dihydroergotamine long-term, your doctor may want to check your heart function periodically using an electrocardiograph or ECG (sometimes called an EKG), a machine that measures electrical activity of the heart.
Since dihydroergotamine is used on an as-needed basis, you are not likely to miss a dose. Do not use more than 3 injections of dihydroergotamine per day or more than 6 injections per week.
another ergot medicine such as ergotamine (Ergomar, Cafergot, Migergot), dihydroergotamine (Migranal), or methylergonovine (Methergine); or
almotriptan (Axert), eletriptan (Relpax), frovatriptan (Frova), naratriptan (Amerge), sumatriptan (Imitrex), rizatriptan (Maxalt, Maxalt-MLT), or zolmitriptan (Zomig).
Grapefruit and grapefruit juice may interact with dihydroergotamine injection and lead to potentially dangerous effects. Discuss the use of grapefruit products with your doctor.
fast or slow heart rate, swelling or itching in any part of your body;
chest pain spreading to the arm or shoulder, and nausea, sweating, or general ill feeling;
sudden numbness or weakness, sudden headache, confusion, or problems with vision, speech, or balance;
leg weakness, muscle pain in your arms or legs;
numbness, tingling, and a pale or blue-colored appearance in your fingers or toes;
stomach cramps, diarrhea that may be bloody;
cough with stabbing chest pain and trouble breathing; or
dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, shortness of breath).
Less serious side effects may include:
headache, dizziness, feeling anxious;
diarrhea;
sweating, mild skin rash, redness or tingly feeling under your skin.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Migraine:
IM or subcutaneous: Initial dose: 1 mg given as quickly as possible after the first symptom of headache. Additional 1 mg doses can be given hourly until the headache has stopped or a total dose of 3 mg has been reached. The total weekly dose should not exceed 6 mg.
IV: Initial dose: 1 mg given as quickly as possible after the first symptom of headache. Additional 1 mg doses can be given hourly until the headache has stopped or a total dose of 2 mg has been reached. The total weekly dose should not exceed 6 mg.
Intranasal: 1 spray (0.5 mg) into each nostril (total = 1 mg). Repeat if needed within 15 minutes to a maximum of 4 sprays (2 mg) per day. The total weekly dose should not exceed 8 sprays (4 mg).
Usual Adult Dose for Cluster Headache:
IM or subcutaneous: Initial dose: 1 mg given as quickly as possible after the first symptom of headache. Additional 1 mg doses can be given hourly until the headache has stopped or a total dose of 3 mg has been reached. The total weekly dose should not exceed 6 mg.
IV: Initial dose: 1 mg given as quickly as possible after the first symptom of headache. Additional 1 mg doses can be given hourly until the headache has stopped or a total dose of 2 mg has been reached. The total weekly dose should not exceed 6 mg.
Many drugs can interact with dihydroergotamine. Below is just a partial list. Tell your doctor if you are using:
zileuton (Zyflo);
nicotine (Nicoderm, Nicorette);
cold or allergy medications, diet pills, stimulants, or medication to treat ADHD (such as Ritalin or Adderall);
an antidepressant such fluoxetine (Prozac), sertraline (Zoloft), and others;
fluconazole (Diflucan) or other antifungal medication; or
heart or blood pressure medication such as atenolol (Tenormin), carvedilol (Coreg), metoprolol (Lopressor, Toprol), propranolol (Inderal, InnoPran), and others.
This list is not complete and other drugs may interact with dihydroergotamine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
See also: dihydroergotamine side effects (in more detail)
Treating high blood pressure and chronic stable angina (chest pain). It may be used alone or in combination with other medicines. It may also be used for other conditions as determined by your doctor.
Diltiazem 24-Hour Extended-Release Beads Capsules are a calcium channel blocker. It works by relaxing (dilating) your blood vessels, lowering blood pressure, and decreasing heart rate, which lowers the workload of the heart. It also dilates coronary arteries, which increases blood flow to the heart.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Diltiazem 24-Hour Extended-Release Beads Capsules. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Diltiazem 24-Hour Extended-Release Beads Capsules. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Diltiazem 24-Hour Extended-Release Beads Capsules may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Diltiazem 24-Hour Extended-Release Beads Capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Diltiazem 24-Hour Extended-Release Beads Capsules.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; dizziness; facial flushing; headache; lightheadedness; tiredness; weakness.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); chest pain; fainting; fast, slow, or irregular heartbeat; fever, chills, or sore throat; hallucinations; mood or mental changes; personality changes; reddened, blistered, or swollen skin; severe or persistent dizziness, lightheadedness, nausea, or vomiting; shortness or breath; sudden weight gain; swelling of the feet, ankles, or hands; symptoms of liver problems (eg, dark urine, pale stools, yellowing of the skin or eyes); tender, bleeding, or swollen gums; unusual bleeding or bruising; unusual or persistent tiredness or weakness; vision changes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Diltiazem side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include confusion; difficulty breathing, especially when lying down; dizziness; drowsiness; fainting; lightheadedness, especially when standing; loss of consciousness; nausea; nervousness; slurred speech; unusual weakness; very slow heart rate.
Store Diltiazem 24-Hour Extended-Release Beads Capsules at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Diltiazem 24-Hour Extended-Release Beads Capsules out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Diltiazem 24-Hour Extended-Release Beads Capsules. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Irinto may be available in the countries listed below.
Irinotecan hydrochloride trihydrate (a derivative of Irinotecan) is reported as an ingredient of Irinto in the following countries:
International Drug Name Search
Loperamid Domesco may be available in the countries listed below.
Loperamide is reported as an ingredient of Loperamid Domesco in the following countries:
International Drug Name Search
Relieving occasional constipation and irregularity. It may also be used for other conditions as determined by your doctor.
Dulcolax Suppositories are a stimulant laxative. It acts directly on the bowels, stimulating the bowel muscles to cause a bowel movement.
Contact your doctor or health care provider right away if any of these apply to you.
Tell your health care provider if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Dulcolax Suppositories. However, no specific interactions with Dulcolax Suppositories are known at this time.
Ask your health care provider if Dulcolax Suppositories may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Dulcolax Suppositories as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Dulcolax Suppositories.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Cramps; faintness; stomach discomfort.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Dulcolax side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include diarrhea; stomach cramps.
Store Dulcolax Suppositories at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store in a tightly closed container away from heat, moisture, and light. Do not store in the bathroom. Keep Dulcolax Suppositories out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Dulcolax Suppositories. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Dibrolax may be available in the countries listed below.
Sodium Picosulfate is reported as an ingredient of Dibrolax in the following countries:
International Drug Name Search
Ketotifen Ratiopharm may be available in the countries listed below.
Ketotifen fumarate (a derivative of Ketotifen) is reported as an ingredient of Ketotifen Ratiopharm in the following countries:
International Drug Name Search
Novador may be available in the countries listed below.
Cefuroxime axetil (a derivative of Cefuroxime) is reported as an ingredient of Novador in the following countries:
Cefuroxime sodium salt (a derivative of Cefuroxime) is reported as an ingredient of Novador in the following countries:
International Drug Name Search
Cavinton Forte may be available in the countries listed below.
Vinpocetine is reported as an ingredient of Cavinton Forte in the following countries:
International Drug Name Search
In the US, Lantus (insulin glargine systemic) is a member of the drug class insulin and is used to treat Diabetes - Type 1 and Diabetes - Type 2.
US matches:
UK matches:
Insulin Glargine is reported as an ingredient of Lantus in the following countries:
Zolpidem tartrate (a derivative of Zolpidem) is reported as an ingredient of Lantus in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Generic Name: dirithromycin (Oral route)
dye-rith-roe-MYE-sin
In the U.S.
Available Dosage Forms:
Therapeutic Class: Antibiotic
Chemical Class: Macrolide
Dirithromycin is used to treat bacterial infections in many different parts of the body. It works by killing bacteria or preventing their growth. However, this medicine will not work for colds, flu, or other virus infections.
Dirithromycin was available only with your doctor's prescription.
Dirithromycin is no longer available in the United States.
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Studies on this medicine have been only in adult patients, and there is no specific information comparing use of dirithromycin in children with use in other age groups.
This medicine has been tested in a limited number of elderly patients and has not been shown to cause different side effects or problems in older people than it does in younger adults.
| Pregnancy Category | Explanation | |
|---|---|---|
| All Trimesters | C | Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women. |
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.
Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:
This section provides information on the proper use of a number of products that contain dirithromycin. It may not be specific to Dynabac. Please read with care.
Dirithromycin should be taken with food or within 1 hour after eating.
To help clear up your infection completely, keep taking dirithromycin for the full time of treatment, even if you begin to feel better after a few days. If you stop taking this medicine too soon, your symptoms may return.
Do not cut, crush, or chew dirithromycin tablets.
The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
Keep out of the reach of children.
Do not keep outdated medicine or medicine no longer needed.
If your symptoms do not improve within a few days, or if they become worse, check with your doctor.
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor as soon as possible if any of the following side effects occur:
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
See also: Dynabac side effects (in more detail)
The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.
Cotrim-Diolan may be available in the countries listed below.
Sulfamethoxazole is reported as an ingredient of Cotrim-Diolan in the following countries:
Trimethoprim is reported as an ingredient of Cotrim-Diolan in the following countries:
International Drug Name Search
Cavea may be available in the countries listed below.
Calcium Phosphate is reported as an ingredient of Cavea in the following countries:
Colecalciferol is reported as an ingredient of Cavea in the following countries:
International Drug Name Search
Symptoms of menopause and premenstrual syndrome (PMS). It may also have other uses. Check with your pharmacist for more details regarding the particular brand you use.
Black Cohosh is an herbal product. It has a similar effect to estrogen, a natural hormone in the body, which controls the menstrual cycle.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Black Cohosh. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Black Cohosh. However, no specific interactions are known at this time.
This may not be a complete list of all interactions that may occur. Ask your health care provider if Black Cohosh may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Black Cohosh as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Black Cohosh.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Dizziness; nausea; stomach discomfort; vomiting.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Black Cohosh side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Store at room temperature away from heat, moisture, and light unless otherwise directed on the package label. Do not store in the bathroom. Most herbal products are not in childproof containers. Keep Black Cohosh out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Black Cohosh. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Epilease may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Potassium Bromide is reported as an ingredient of Epilease in the following countries:
International Drug Name Search
In the US, Aromasin (exemestane systemic) is a member of the following drug classes: aromatase inhibitors, hormones/antineoplastics and is used to treat Breast Cancer.
US matches:
Exemestane is reported as an ingredient of Aromasin in the following countries:
International Drug Name Search
Diathynil may be available in the countries listed below.
Biotin is reported as an ingredient of Diathynil in the following countries:
International Drug Name Search
Novacarel may be available in the countries listed below.
Mesna is reported as an ingredient of Novacarel in the following countries:
International Drug Name Search
In the US, Potaba (potassium aminobenzoate systemic) is a member of the drug class oral nutritional supplements.
US matches:
UK matches:
Aminobenzoic Acid potassium salt (a derivative of Aminobenzoic Acid) is reported as an ingredient of Potaba in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Cefophar may be available in the countries listed below.
Cefoperazone sodium salt (a derivative of Cefoperazone) is reported as an ingredient of Cefophar in the following countries:
International Drug Name Search
Lansoprazolo EG may be available in the countries listed below.
Lansoprazole is reported as an ingredient of Lansoprazolo EG in the following countries:
International Drug Name Search
Visderm may be available in the countries listed below.
Amcinonide is reported as an ingredient of Visderm in the following countries:
International Drug Name Search
Histafen may be available in the countries listed below.
Chlorphenamine maleate (a derivative of Chlorphenamine) is reported as an ingredient of Histafen in the following countries:
International Drug Name Search
Cebralat may be available in the countries listed below.
Cilostazol is reported as an ingredient of Cebralat in the following countries:
International Drug Name Search
Lusafan F may be available in the countries listed below.
Clotrimazole is reported as an ingredient of Lusafan F in the following countries:
International Drug Name Search
Pravat may be available in the countries listed below.
Pravastatin sodium salt (a derivative of Pravastatin) is reported as an ingredient of Pravat in the following countries:
International Drug Name Search
Calcio Mefolinato Hexal may be available in the countries listed below.
Calcium Levofolinate is reported as an ingredient of Calcio Mefolinato Hexal in the following countries:
International Drug Name Search
Paraldehyde DBL may be available in the countries listed below.
Paraldehyde is reported as an ingredient of Paraldehyde DBL in the following countries:
International Drug Name Search
Carboplatin Amphar may be available in the countries listed below.
Carboplatin is reported as an ingredient of Carboplatin Amphar in the following countries:
International Drug Name Search
Cétirizine RPG may be available in the countries listed below.
Cetirizine dihydrochloride (a derivative of Cetirizine) is reported as an ingredient of Cétirizine RPG in the following countries:
International Drug Name Search
Aramil may be available in the countries listed below.
Glimepiride is reported as an ingredient of Aramil in the following countries:
International Drug Name Search
Ondansetron Lazar may be available in the countries listed below.
Ondansetron hydrochloride (a derivative of Ondansetron) is reported as an ingredient of Ondansetron Lazar in the following countries:
International Drug Name Search
Nalbufina Gemepe may be available in the countries listed below.
Nalbuphine hydrochloride (a derivative of Nalbuphine) is reported as an ingredient of Nalbufina Gemepe in the following countries:
International Drug Name Search
Domstal-O may be available in the countries listed below.
Domperidone is reported as an ingredient of Domstal-O in the following countries:
Omeprazole is reported as an ingredient of Domstal-O in the following countries:
International Drug Name Search
Ondansetron O.R.C.A.pharm may be available in the countries listed below.
Ondansetron hydrochloride (a derivative of Ondansetron) is reported as an ingredient of Ondansetron O.R.C.A.pharm in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Bacitracin methylene disalicylate (a derivative of Bacitracin) is reported as an ingredient of Aviax in the following countries:
Nicarbazin is reported as an ingredient of Aviax in the following countries:
Roxarsone is reported as an ingredient of Aviax in the following countries:
Salinomycin sodium salt (a derivative of Salinomycin) is reported as an ingredient of Aviax in the following countries:
Semduramicin is reported as an ingredient of Aviax in the following countries:
Semduramicin sodium salt (a derivative of Semduramicin) is reported as an ingredient of Aviax in the following countries:
Virginiamycin is reported as an ingredient of Aviax in the following countries:
International Drug Name Search
Phloroglucinol hydraté may be available in the countries listed below.
Phloroglucinol hydraté is also known as Phloroglucinol (JAN)
International Drug Name Search
Glossary
| JAN | Japanese Accepted Name |
Captopril-R may be available in the countries listed below.
Captopril is reported as an ingredient of Captopril-R in the following countries:
International Drug Name Search
Forticine may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Forticine in the following countries:
International Drug Name Search
Class: Antineoplastic Agents
VA Class: AN900
Chemical Name: (±) - N - [4 - cyano - 3 - (trifluoromethyl)phenyl] - 3 - [(4 - fluorophenyl)sulfonyl] - 2 - hydroxy - 2 - methylpropanamide
Molecular Formula: C18H14F4N2O4S
CAS Number: 90357-06-5
Brands: Casodex
Antineoplastic agent; a nonsteroidal antiandrogen.1 3 4 14 40 43
Palliative treatment of metastatic (stage D2) prostate cancer; should be used in conjunction with a luteinizing hormone-releasing hormone (LHRH) analog (e.g., goserelin, leuprolide acetate).1 2 3 9 18
Initiate bicalutamide and LHRH analog concomitantly.1 35 43
Administer orally once daily at the same time each day (morning or evening) without regard to meals.1 35 43
50 mg once daily.1 3 9 40 43 Duration of combined therapy with LHRH analog depends on clinical response.35
Known hypersensitivity to bicalutamide or any ingredient in the formulation.1
Should not be used in women, particularly for conditions that are not serious or life-threatening.1
Women who are or may become pregnant.1 (See Fetal/Neonatal Morbidity and Mortality under Cautions.)
May cause fetal harm; contraindicated in pregnant women.1
If used during pregnancy or if patient becomes pregnant, apprise of potential fetal hazard.1
Severe liver injury reported, sometimes resulting in hospitalization and/or death;1 26 manifestations generally occurred within first 3–4 months.1
Possible hepatitis or marked increases in serum concentrations of hepatic transaminases.1
Measure serum transaminase concentrations prior to initiation of therapy, at regular intervals during the first 4 months, and periodically thereafter.1
Immediately measure serum transaminase (especially ALT) concentrations if manifestations suggestive of liver dysfunction occur.1
Immediately discontinue if jaundice develops or serum ALT concentration is >2 times ULN; monitor liver function closely thereafter.1
Regularly monitor serum PSA to assess response; if PSA increases, evaluate for possible disease progression.1 17
For patients with objective progression of disease and elevated serum PSA, consider temporarily withdrawing bicalutamide while continuing LHRH analog.1 35 36 37 Withdrawal of bicalutamide may be associated with PSA decrease.31 44
Ensure accuracy of prescription; similarity in spelling of Casodex (the trade name for bicalutamide) and Kapidex (former trade name for dexlansoprazole, a proton-pump inhibitor) may result in errors.217 218 219 223
Category X.1 (See Fetal/Neonatal Morbidity and Mortality and also Contraindications under Cautions.)
Not known whether bicalutamide is distributed into milk;1 use caution.1
Safety and efficacy not established.1
Use with caution in patients with moderate to severe hepatic impairment.1 3
Consider periodic liver function tests in patients with hepatic impairment receiving long-term therapy.1 35
Not intended for use in women, particularly for nonserious or nonlife-threatening conditions.1
Combined therapy with LHRH analog: hot flashes, pain (including abdominal, back, and pelvic pain), asthenia, constipation, infection, nausea, dyspnea, diarrhea.1
Gynecomastia and breast pain frequent if bicalutamide used as monotherapy.1
Does not induce CYP isoenzymes.1 Pharmacokinetic interaction unlikely with drugs metabolized by CYP isoenzymes.1
Drug | Interaction | Comments |
|---|---|---|
Alcohol | Increased risk of facial flushing41 | Avoid alcohol consumption during therapy41 |
LHRH analog (e.g., goserelin, leuprolide) | Pharmacokinetic interaction unlikely1 | |
Warfarin and other coumarins | Decreased anticoagulant protein binding and increased plasma concentrations; increased anticoagulant effects1 | Monitor PT; adjust anticoagulant dosage as needed1 |
Well-absorbed following oral administration; absolute bioavailability is unknown.1
Food has no clinically important effect on rate or extent of absorption.1
96%.1
Undergoes stereospecific metabolism in the liver.1
Active R-enantiomer is predominantly oxidized to an inactive metabolite followed by glucuronidation.1 Inactive S-enantiomer is principally metabolized by glucuronidation.1
S-enantiomer is rapidly cleared relative to the R-enantiomer; R-enantiomer accounts for about 99% of total steady-state plasma concentrations.1
Both parent and metabolite glucuronides are eliminated in urine and feces.1
Approximately 6 days.1
Half-life of R-enantiomer was increased approximately 76% in patients with severe hepatic impairment.1
20–25°C.1
A selective antiandrogen with no androgenic or progestational activity in various animal models.12 17 43
Competitively blocks nuclear androgen receptors in target tissues (e.g., adrenal cortex, prostate, seminal vesicles).1 11 12 14 16 34 43
Blockade of androgen receptors in the hormone-sensitive tumor cells may result in growth arrest or transient tumor regression through inhibition of androgen-dependent DNA and protein synthesis.1 11 12 14 16 34 43
Inhibits initial androgenic stimulation and potential exacerbation of symptoms (e.g., bone pain, urinary obstruction, liver pain, impending spinal cord compression) associated with the first month of LHRH analog therapy.8 10 14 16 18 21 23 25 40
Risk of potential liver toxicity.1
Risk of facial flushing,1 41 particularly if used in conjunction with alcohol.41 Avoidance of alcohol recommended if flushing occurs.41
Importance of initiating bicalutamide concomitantly with LHRH analog and of not interrupting or discontinuing therapy without consulting a clinician.1
If used in women, importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.1
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as concomitant illnesses.1
Importance of informing patients of other important precautionary information.1 (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral | Tablets, film- coated | 50 mg | Casodex | AstraZeneca |
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Bicalutamide 50MG Tablets (TEVA PHARMACEUTICALS USA): 30/$59.99 or 90/$159.97
Casodex 50MG Tablets (ASTRAZENECA): 30/$536.99 or 90/$1608.02
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions August 2010. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
1. AstraZeneca. Casodex (bicalutamide) tablets prescribing information. Wilmington, DE; 2002 Sep.
2. Anon. Drugs of choice for cancer chemotherapy. Med Lett Drugs Ther. 2000; 42: 83-92.
3. Blackledge G. Casodexmechanisms of action and opportunities for usage. Cancer. 1993; 72(Suppl):3830-3. [IDIS 323230] [PubMed 7504578]
4. Cockshott ID, Sotaniemi EA, Cooper KJ et al. The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function. Br J Clin Pharmacol. 1993; 36:339-43. [IDIS 321958] [PubMed 12959312]
5. Wilson JD. Androgens. In: Gilman AG, Rall TW, Nies AS et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press; 1990:1413-1430.
6. Prostate cancer. From: CancerNet/PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2001 Oct.
7. Schering. Eulexin (flutamide) capsules prescribing information (dated 1994 Jul). In: Physicians’ desk reference. 49th ed. Montvale, NJ: Medical Economics Company Inc; 1995:2253-4.
8. Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989; 321:419-24. [IDIS 258377] [PubMed 2503724]
9. Schellhammer P, Sharifi R, Block N et al et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology. 1995; 45:745-52. [PubMed 7538237]
10. Dole EJ, Holdsworth MT. Nilutamide: an anitandrogen for the treatment of prostate cancer. Ann Pharmacother. 1997; 31: 65-75.
11. Geller J. Basis for hormonal management of advanced prostate cancer. Cancer. 1993; 71(Suppl):1039-45. [IDIS 313140] [PubMed 7679038]
12. McLeod DG. Antiandrogenic drugs. Cancer. 1993; 71(Suppl):1046-9. [IDIS 313141] [PubMed 8428326]
13. Migliari R, Muscas G, Usai E. Effect of Casodex on sleep-related erections in patients with advanced prostate cancer. J Urol. 1992; 148:338-41. [IDIS 300700] [PubMed 1378907]
14. Denis L. Prostate cancer: primary hormonal treatment. Cancer. 1993; 71(Suppl):1050-8. [IDIS 313142] [PubMed 8428327]
15. Smith PH. Deferred therapy in patients with advanced disease. Cancer. 1993; 71(Suppl):1074-7. [IDIS 313144] [PubMed 8428330]
16. Daneshgari F, Crawford ED. Endocrine therapy of advanced carcinoma of the prostate. Cancer. 1993; 71(Suppl):1089-97. [IDIS 313146] [PubMed 8428333]
17. Soloway MS, Matzkin H. Antiandrogenic agents as monotherapy in advanced prostatic carcinoma. Cancer. 1993; 71(Suppl):1083-8. [IDIS 313145] [PubMed 8428332]
18. Mahler C. Is disease flare a problem? Cancer. 1993; 72(Suppl):3799-802. (IDIS 323226)
19. Sagalowsky AI, Wilson JD. Hyperplasia and carcinoma of the prostate. In: Wilson JD, Braunwald E, Isselbacher KJ et al, eds. Harrison’s principles of internal medicine. 12th ed. New York: McGraw-Hill Company; 1991: 1629-33.
20. Brendler CB. Diseases of the prostate. In: Wyngaarden JB, Smith LH Jr, Bennett JC, eds. Cecil textbook of medicine. 19th ed. Philadelphia: WB Saunders Company; 1992:1351-5.
21. Chrisp P, Goa KL. Goserelin: a review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions. Drugs. 1991; 41:254-88. [PubMed 1709853]
22. Vogelzang NJ, Kennealey GT. Recent developments in endocrine treatment of prostate cancer. Cancer. 1992; 70:966-76. [IDIS 300575] [PubMed 1386283]
23. Santen RJ. Endocrine treatment of prostate cancer. J Clin Endocrinol Metab. 1992; 75:685-9. [IDIS 302863] [PubMed 1517354]
24. Tyrrell CJ, Altwein JE, Klippel F et al et al. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. J Urol. 1991; 146:1321-6. [IDIS 290344] [PubMed 1834864]
25. Kuhn JM, Billebaud T, Navratil H et al. Prevention of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med. 1989; 321:413-8. [IDIS 258376] [PubMed 2503723]
26. Dawson LA, Chow E, Morton G. Fulminant hepatic failure associated with bicalutamide. Urology. 1997; 49:283-4. [PubMed 9037299]
27. Soloway MS. Newer methods of hormonal therapy for prostate cancer. Urology. 1984; 24(Suppl):30-8. [IDIS 198972] [PubMed 6437034]
28. Paulson DF. Management of metastatic prostatic cancer. Urology. 1985; 25:(Suppl):49-52.
29. Tolis G, Ackman D, Stellos A et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Med Sci. 1982; 79:1658-62.
30. Elder JS, Catalona WJ. Management of newly diagnosed metastatic carcinoma of the prostate. Urol Clin North Am. 1984; 11:283-95. [PubMed 6428022]
31. Nieh PT. Withdrawal phenomenon with the antiandrogen casodex. J Urol. 1995; 153:1070-2. [IDIS 342239] [PubMed 7531785]
32. Crawford ED. Withdrawal phenomenon with the antiandrogen Casodex: editorial comments. J Urol. 1995; 153:1072.
33. Scher HI, Kelly WK. Withdrawal phenomenon with the antiandrogen Casodex: editorial comments. J Urol. 1995; 153:1072-3.
34. Kennealey GT, Furr BJA. Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma. Urol Clin North Am. 1991; 18:99-110. [PubMed 1992575]
35. Zeneca Pharmaceuticals, Wilmington, DE: Personal communication.
36. Cersosimo RJ, Carr D. Prostate cancer: current and evolving strategies. Am J Health-Syst Pharm. 1996; 53:381-96. [IDIS 360612] [PubMed 8673658]
37. McLeod DG, Kolvenbag GJCM. Defining the role of antiandrogens in the treatment of prostate cancer. Urology. 1996; 47(Suppl 1A):85-9. [PubMed 8560682]
39. Erlichman C, Loprinzi CL. Hormonal therapies. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 5th ed. Philadelphia, PA: J. B. Lippincott; 1997:395-405.
40. Anon. Bicalutamide for prostate cancer. Med Lett Drugs Ther. 1996; 38:56-7. [PubMed 8657047]
41. Kirschenbaum A. Management of hormonal treatment effects. Cancer. 1995; 75:1983-6.
42. Schellhammer PF, Sharifi R, Block NL et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology. 1997; 50:330-6. [PubMed 9301693]
43. Goa KL, Spencer CM. Bicalutamide in advanced prostate cancer: a review. Drugs Aging. 1998; 12:401-22. [PubMed 9606617]
44. Culig Z, Hoish A, Hittmair A et al. Androgen receptor gene mutations in prostate cancer: implications for disease progression and therapy. Drug Aging. 1997; 10:50-8.
217. US Food and Drug Administration. FDA approves name change for heartburn drug Kapidex. Rockville, MD; 2010 Mar 4. News release from FDA website ().
218. Institute for Safe Medication Practices. Kapidex-Casodex confusion. ISMP Medication Safety Alert! Community/Ambulatory Care edition. Horsham, PA; 2009 Jul. From ISMP website ().
219. Institute for Safe Medication Practices. ISMP quarterly action agenda July–September 2009. ISMP Medication Safety Alert! Acute Care edition. Horsham, PA; 2009 Oct 8. From ISMP website ().
222. Takeda Pharmaceuticals America. Dexilant (dexlansoprazole) delayed-release capsules prescribing information. Deerfield, IL; 2010 Mar.
223. Institute for Safe Medication Practices. Progress with preventing name confusion errors. ISMP Medication Safety Alert! Acute Care edition. Horsham, PA; 2007 Aug 9. From ISMP website ().
